EP2762489A4 - GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - Google Patents

GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Info

Publication number
EP2762489A4
EP2762489A4 EP12836998.0A EP12836998A EP2762489A4 EP 2762489 A4 EP2762489 A4 EP 2762489A4 EP 12836998 A EP12836998 A EP 12836998A EP 2762489 A4 EP2762489 A4 EP 2762489A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition containing
containing same
glycosylated polypeptide
glycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12836998.0A
Other languages
German (de)
French (fr)
Other versions
EP2762489A9 (en
EP2762489B1 (en
EP2762489A1 (en
Inventor
Izumi Sakamoto
Kazuhiro Fukae
Katsunari Tezuka
Keisuke Tazuru
Masatoshi Maeda
Yasuhiro Kajihara
Takashi Tsuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glytech Inc
Original Assignee
Glytech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glytech Inc filed Critical Glytech Inc
Publication of EP2762489A1 publication Critical patent/EP2762489A1/en
Publication of EP2762489A9 publication Critical patent/EP2762489A9/en
Publication of EP2762489A4 publication Critical patent/EP2762489A4/en
Application granted granted Critical
Publication of EP2762489B1 publication Critical patent/EP2762489B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP12836998.0A 2011-10-01 2012-09-28 Glycosylated polypeptide and pharmaceutical composition containing same Active EP2762489B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011218793 2011-10-01
PCT/JP2012/075262 WO2013047846A1 (en) 2011-10-01 2012-09-28 Glycosylated polypeptide and pharmaceutical composition containing same

Publications (4)

Publication Number Publication Date
EP2762489A1 EP2762489A1 (en) 2014-08-06
EP2762489A9 EP2762489A9 (en) 2015-02-11
EP2762489A4 true EP2762489A4 (en) 2015-05-06
EP2762489B1 EP2762489B1 (en) 2018-03-28

Family

ID=47995870

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12836998.0A Active EP2762489B1 (en) 2011-10-01 2012-09-28 Glycosylated polypeptide and pharmaceutical composition containing same

Country Status (16)

Country Link
US (1) US10358470B2 (en)
EP (1) EP2762489B1 (en)
JP (1) JP6153470B2 (en)
KR (1) KR101979045B1 (en)
CN (2) CN104080803B (en)
AU (1) AU2012317325B2 (en)
BR (1) BR112014007766B1 (en)
CA (1) CA2850469C (en)
DK (1) DK2762489T3 (en)
IN (1) IN2014CN02982A (en)
MY (1) MY168902A (en)
PH (1) PH12014500694B1 (en)
RU (1) RU2636456C2 (en)
SG (2) SG11201401071YA (en)
TW (1) TWI633115B (en)
WO (1) WO2013047846A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101979045B1 (en) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 Glycosylated polypeptide and pharmaceutical composition containing same
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
CN114685645B (en) * 2020-12-30 2025-03-21 深圳翰宇药业股份有限公司 A synthetic method of semaglutide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
US20040115168A1 (en) * 2001-10-10 2004-06-17 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US20060040353A1 (en) * 2000-06-28 2006-02-23 Davidson Robert C Production of galactosylated glycoproteins in lower eukaryotes
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
ES2218806T3 (en) 1997-01-16 2004-11-16 Neose Technologies, Inc. PRACTICAL SITING IN VITRO OF RECOMBINANT GLICOPROTEINS.
DE19717864C2 (en) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Human recombinant interferon beta, process for its preparation and its use
BR9910023A (en) * 1998-04-28 2000-12-26 Applied Research Systems Polyol conjugates-ifn-beta
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
DE60037978T2 (en) * 1999-12-08 2008-05-21 Amgen Inc., Thousand Oaks INTERFERON SIMILAR MOLECULES AND THEIR USES
AU2001273385B2 (en) 2000-09-08 2005-04-07 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
JP2004534523A (en) 2001-02-27 2004-11-18 マキシゲン・エイピーエス Novel interferon beta-like molecule
CA2441095A1 (en) 2001-03-15 2002-09-26 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified interferon beta with reduced immunogenicity
EP2305312B1 (en) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
CA2469487A1 (en) 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
PL377612A1 (en) * 2002-09-27 2006-02-06 Biogen Idec Ma Inc. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β
AU2003277088A1 (en) 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
AU2003292792A1 (en) 2002-12-26 2004-07-22 Kajihara, Yasuhiro Sugar-chain asparagine derivatives and processes for the preparation thereof
EP1666496B1 (en) 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
JP2007526317A (en) 2004-03-01 2007-09-13 エンゾン ファーマスーティカルズ インコーポレイテッド Interferon-beta polymer conjugate
EP1789074A4 (en) 2004-08-09 2009-08-12 Alios Biopharma Inc Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
RU2392963C2 (en) * 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Synthetic versions of hyperglycolised protease-resistive polypeptide, oral compositions and methods of using such versions
KR100781666B1 (en) 2004-11-02 2007-12-03 신영기 Human Interferon-beta Variants
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
TWI423821B (en) 2007-06-19 2014-01-21 Glucose-containing glucagon-like peptide-1
AU2008283317B2 (en) 2007-07-31 2012-08-02 Glytech, Inc. Method for producing peptide
JP2009242372A (en) 2008-03-11 2009-10-22 Yokohama City Univ Erythropoietin derivative having uniform sugar chain structure
JP5604297B2 (en) 2008-06-17 2014-10-08 株式会社糖鎖工学研究所 Glycosylated GLP-1 peptide
KR20110067097A (en) * 2008-08-19 2011-06-21 오츠카 가가쿠 가부시키가이샤 Preparation method and screening method of glycoprotein
WO2012051615A1 (en) 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
SG193377A1 (en) 2011-03-10 2013-10-30 Glytech Inc Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide
ES2774284T3 (en) 2011-06-29 2020-07-20 Kyowa Kirin Co Ltd Method to purify antithrombin
KR101979045B1 (en) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 Glycosylated polypeptide and pharmaceutical composition containing same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
US20060040353A1 (en) * 2000-06-28 2006-02-23 Davidson Robert C Production of galactosylated glycoproteins in lower eukaryotes
US20040115168A1 (en) * 2001-10-10 2004-06-17 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARY WALSH ET AL: "Post-translational modifications in the context of therapeutic proteins", NATURE BIOTECHNOLOGY, vol. 24, no. 10, 1 October 2006 (2006-10-01), pages 1241 - 1252, XP055024914, ISSN: 1087-0156, DOI: 10.1038/nbt1252 *
See also references of WO2013047846A1 *

Also Published As

Publication number Publication date
EP2762489A9 (en) 2015-02-11
SG10201602076QA (en) 2016-04-28
CA2850469C (en) 2020-07-07
CN104080803A (en) 2014-10-01
US10358470B2 (en) 2019-07-23
RU2014116550A (en) 2015-10-27
KR101979045B1 (en) 2019-05-15
RU2636456C2 (en) 2017-11-23
MY168902A (en) 2018-12-04
BR112014007766A2 (en) 2017-04-04
DK2762489T3 (en) 2018-07-02
CN104080803B (en) 2020-08-04
JP6153470B2 (en) 2017-06-28
CN109134642A (en) 2019-01-04
AU2012317325B2 (en) 2016-10-06
EP2762489B1 (en) 2018-03-28
EP2762489A1 (en) 2014-08-06
US20140369964A1 (en) 2014-12-18
IN2014CN02982A (en) 2015-07-03
SG11201401071YA (en) 2014-08-28
CA2850469A1 (en) 2013-04-04
TW201321404A (en) 2013-06-01
KR20140095051A (en) 2014-07-31
PH12014500694B1 (en) 2020-01-31
BR112014007766B1 (en) 2022-05-10
WO2013047846A1 (en) 2013-04-04
TWI633115B (en) 2018-08-21
JPWO2013047846A1 (en) 2015-03-30
PH12014500694A1 (en) 2014-05-12
AU2012317325A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
EP2752425A4 (en) GLYCOSYLATED POLYPEPTIDE AND DRUG COMPOSITION CONTAINING THE POLYPEPTIDE
IL262667B (en) An isolated polynucleotide encoding a polypeptide and a pharmaceutical composition containing the isolated polynucleotide
IL233134A0 (en) Pharmaceutical preparations containing glitazones and nrf2 activators
BR112013014644A2 (en) pharmaceutical composition and complex
IL230662A0 (en) Indazole-type substances, preparations containing these substances and their uses
EP2746394A4 (en) ANTIBODY AND COMPOSITION CONTAINING THE SAME
PL2776460T3 (en) Fusion protein containing interleukin 4 and interleukin 10
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
EP2789245A4 (en) EMULSION COMPOSITION AND COMPOSITION CONTAINING THE SAME
BR112015011111A2 (en) multifunctional protein and pharmaceutical formulation
EP2642979A4 (en) PHARMACEUTICAL COMPOSITION
EP2889308A4 (en) SUPERFAMIL ALPHA O CONOTOXIN PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
FR2958157B1 (en) COSMETIC AND PHARMACEUTICAL COMPOSITION COMPRISING N-ACETYL-GLUCOSAMINE-6-PHOSPHATE
EP2484697A4 (en) ANTIPODOPLANIN ANTIBODY AND PHARMACEUTICAL COMPOSITION CONTAINING ANTIPODOPLANIN ANTIBODY
EP2589382A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING LEVOCARNITINE AND DOBESILATE
PL2651409T3 (en) NEW PHARMACEUTICAL COMPOSITION CONTAINING NSAIDS AND CYCLODECSTRIN
SMT201600097B (en) LIQUID PHARMACEUTICAL COMPOSITION INCLUDING NITISONE
IL229956B (en) 1mphosph peptides and ingredients containing them
IL228403A0 (en) Preparations containing anti-influenza antibodies and osetamivir and their uses
BR112015002646A2 (en) compound and pharmaceutical composition
HUE036784T2 (en) Pharmaceutical preparations containing Alisporivir
EP2762489A4 (en) GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
EP2752424A4 (en) GLYCOSYLATED POLYPEPTIDE AND DRUG COMPOSITION CONTAINING THE POLYPEPTIDE
EP2789607A4 (en) PYRIDONE DERIVATIVE AND MEDICINE CONTAINING THE SAME
BR112013014937A2 (en) liquid formulation containing halymeniales protein and carrageenan lambda

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150407

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20150330BHEP

Ipc: C07K 1/06 20060101ALI20150330BHEP

Ipc: C07K 14/565 20060101AFI20150330BHEP

Ipc: A61P 31/12 20060101ALI20150330BHEP

Ipc: A61P 35/00 20060101ALI20150330BHEP

Ipc: A61P 25/00 20060101ALI20150330BHEP

Ipc: A61K 38/21 20060101ALI20150330BHEP

Ipc: A61K 38/00 20060101ALI20150330BHEP

Ipc: A61P 1/16 20060101ALI20150330BHEP

17Q First examination report despatched

Effective date: 20170519

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20171120

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 983334

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012044586

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180628

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180328

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180628

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180629

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 983334

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180730

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012044586

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120928

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180328

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180728

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230810

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230808

Year of fee payment: 12

Ref country code: DK

Payment date: 20230914

Year of fee payment: 12

Ref country code: DE

Payment date: 20230808

Year of fee payment: 12

Ref country code: BE

Payment date: 20230818

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20231001

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012044586

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20240930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20240928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240928

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20240930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240930